102 results about "Meticillin" patented technology

The present invention relates to nanosilver-containing antibacterial and antifungal granules ("NAGs"). The NAGs have longlasting inhibitory effect on a broad-spectrum of bacteria and fungi, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C. The NAGs contain ground stalk marrow of the plant Juncus effuses L. which has been dispersed with nanosilver particles. The nanosilver particles are about 1-100 mn in diameter. Each of the nanosilver particles contain a metallic silver core which is surrounded by silver oxide. The present invention also provides a process for making the NAGs. The NAGs can be used in a variety of healthcare and industrial products. Examples of the healthcare products include, but are not limited to, ointments or lotions to treat skin trauma, soaking solutions or cleansing solutions for dental or women hygiene, medications for treating gastrointestinal bacteria infections, sexual related diseases, and eye diseases. Examples of industrial products include, but are not limited to, food preservatives, water disinfectants, paper disinfectants, construction filling materials (to prevent mold formation).

The present invention provides Wall Teichoic Acid biosynthesis inhibitors such as compound 1835F03 (targocil) and related synthetic analogs. The invention also provides pharmaceutical compositions thereof and methods for treating bacterial infection and the suppression of growth of bacterial cells by administering a Wall Teichoic Acid biosynthesis inhibitor. The invention is particularly useful for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). The invention further provides procedures for the syntheses of Wall Teichoic Acid biosynthesis inhibitors. The invention also provides methods for the identification of antibacterial therapeutic agents.

The invention relates generally to novel N-thiolated β-lactams. More specially, the invention relates to the use of these novel antibacterial agents in the treatment or inhibition of methicillin-resistant Staphylococcus aureaus.

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.

Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) in a sample. The present invention provides a diagnostic method comprising modification of sequences of S. aureus by converting non-methylated cytosine residues ultimately into thymidine residues in the target nucleic acid. The invention further provides for the detection of modified sequences derived from the spa gene, the mecA gene, and the integrated SCCmec cassette of S. aureus.

The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant Staphylococcus aureus (MRSA) and other methicillin-resistant bacteria in a sample.

The invention discloses an effective humulus scandens part, the antibacterial activity of the effective humulus scandens part and the application of the effective humulus scandens part to preparation of antibacterial drugs. The whole plants of humulus scandens are used as the raw material, extraction is performed through water or 5% to 100% alcohol, after the primary treatment, the effective humulus scandens part is obtained through the macroporous resin-polyamide resin combination technology or the silica-gel column chromatography and mainly contains flavonoids compounds, the total flavonoid content ranges from 20 percent to 90 percent, and the effective humulus scandens part mainly contains apigenin, luteolin, luteolin-7-O-beta-D-glucoside, cosmosiin and the like. The effective part has the remarkable antibacterial activity and shows high antibacterial activity to clinically methicillin-resistant staphylococcus aureus, methicillin-resistant staphylococcus epidermidis, enterococcus faecium and enterococcus faecalis. The effective humulus scandens part can be used as the raw material of medicines and made into antibacterial drug tablets and capsules and the like and particularly can be used for preparing drugs for treating diseases of the urinary system such as diarrhea, enterogastritis, pyelonephritis and acute nephritis caused by bacterial infection and foods with the digestion aid, prevention and health care functions.

The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequenceshomologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

The invention relates to heterosubstituted N-thiolated beta-lactams, compositions comprising these compounds, methods for their production, and methods of use as antibiotics to inhibit the growth of bacteria. The antibacterial agents of the invention can be administered to a human or animal to treat or inhibit bacterial infection, such as that of Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA).